ICH E2C (R2) Periodic benefit-risk evaluation report - Scientific guideline

This document defines the recommended format and content of a periodic benefit-risk evaluation report (PBRER) and provides an outline of points to be considered in its preparation and submission.
HumanScientific guidelines

Lithuanian is available via eTranslation, the European Commission's machine translation service.

Translate to Lithuanian | Important information about machine translation

PBRER is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the ICH regions. Read together with ICH guideline E2C (R2) - questions and answers, step 5.

Keywords: Periodic benefit-risk evaluation report (PBRER), active substance, fixed dose combination product, efficacy, benefit-risk, periodicity, international birth date, data lock point, reference safety information, cumulative subject exposure, clinical trials, non-interventional studies, medication errors, non-clinical data, literature, late-breaking information, signal, risk

Current effective version

Document history

Share this page